BioSpace News Archive

Business

HSS Appoints Mary E. Cassai, RN to Executive Vice President, Chief Operating Officer

Hospital for Special Surgery announced the appointment of Mary E. Cassai, MPA, BSN, RN, NEA-BC, to Executive Vice President and Chief Operating Officer, following a nationwide search.

June 13, 2023
·
5 min read
BioMidwest

New research from the Stowers Institute reveals the start of Huntington’s disease

Devastating neurodegenerative diseases like Huntington’s, Alzheimer’s, and Parkinson’s are all associated with protein deposits in the brain, known as amyloid.

June 13, 2023
·
5 min read
IRLAB to Present at the Scientific Conference XIV Triennial Meeting of the International Basal Ganglia Society (IBAGS)

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will present an abstract at the IBAGS XIV triennial meeting, held on June 13-16, 2023, in Stockholm, Sweden.

June 13, 2023
·
2 min read
Genetown

CORRECTING and REPLACING Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 (Perfluorohexyloctane Ophthalmic Solution) For the Treatment of Dry Eye Disease in Japan

Senju Pharmaceutical Co., Ltd. and Novaliq GmbH are pleased to announce the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03, the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear evaporation.

June 13, 2023
·
5 min read
Drug Development

HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers

HighField Biopharmaceuticals, a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced the U.S. Food and Drug Administration has granted clearance of the company’s Investigational New Drug application for HF158K1, a drug encapsulated immunoliposome containing doxorubicin.

June 13, 2023
·
3 min read
Business

Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer

Reata Pharmaceuticals, Inc., a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced the appointment of Rajiv Patni, M.D., as Executive Vice President, and Chief Research & Development Officer.

June 13, 2023
·
4 min read
Drug Development

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

Aclaris Therapeutics, Inc. announced the completion of enrollment into ATI-450-RA-202, its Phase 2b trial of oral zunsemetinib in patients with moderate to severe rheumatoid arthritis.

June 13, 2023
·
4 min read
Kalderos’ 2023 annual report highlights costs of systemic challenges in drug discount programs and their impact on drug manufacturers, covered entities, payers and patients

Company reports that since 2016, its tech-enabled platform for Drug Discount Management has identified nearly $1 billion in inaccurate drug discount claims

June 13, 2023
·
3 min read
Business

HepQuant Announces Additions to the Executive Leadership Team to Drive Commercialization

HepQuant, LLC, a leader transforming the management of liver diseases, announces key additions to its executive leadership team.

June 13, 2023
·
4 min read
Biotech Beach

Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular DystrophySafety and Efficacy Results to be Presented at 2023 Parent Project Muscular Dystrophy Annual Conference

Capricor Therapeutics announced that the Company will present 24-month safety and efficacy results from its ongoing HOPE-2 open-label extension study with its lead asset, CAP-1002, for the treatment of Duchenne Muscular Dystrophy at this year’s Parent Project Muscular Dystrophy Annual Conference.

June 13, 2023
·
4 min read